Travere Therapeutics, Inc. TVTX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 98.6%+0.7pp | 97.9%+0.3pp | 97.6%+0.7pp | 96.9%+0.9pp | 96%-0.7pp | |
| Operating margin | -10.6%+2.2pp | -12.8%+8.1pp | -20.9%+30.7pp | -51.6%+31.5pp | -83.1%+55.8pp | |
| Returns | ||||||
| Return on invested capital | -118%-21.9pp | -96.2%— | —— | -636.6%-251pp | -385.6%-138pp | |
| Efficiency | ||||||
| Asset turnover | 1×+0.2× | 0.8×0.0× | 0.8×+0.2× | 0.6×+0.2× | 0.5×+0.1× | |
| Liquidity | ||||||
| Current ratio | 3.1×+0.4× | 2.7×0.0× | 2.7×+0.7× | 2×0.0× | 2.1×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×0.0× | 0.1×-0.1× | 0.2×-2.5× | 2.7×0.0× | 2.7×+1.2× | |
| Net debt / EBITDA | -3.9×— | —— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $1.07-16.5% | $1.29+79.5% | $0.72+94.7% | $0.37-0.9% | $0.37-50.4% | |
| Valuation | ||||||
| Market capitalization | $2.74B-19.8% | $3.42B+60.5% | $2.13B+57.4% | $1.35B-14.9% | $1.59B+4.9% | |
| Price / sales | 5.1×-1.9× | 7×+2.1× | 4.9×+0.8× | 4.1×-1.8× | 5.8×-0.7× | |
| Price / book | 27.8×-2.0× | 29.8×+0.8× | 29×-12.4× | 41.3×-7.1× | 48.4×+22.8× | |
| EV / EBITDA | 166.4×— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Travere Therapeutics, Inc.'s profit margins?
- Travere Therapeutics, Inc. (TVTX) runs a 98.6% gross margin and a -10.6% operating margin, with a -20.3% net margin.
- Where do Travere Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Travere Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.